Drug intelligence / Profile preview

ALG-903

Development stage: Preclinical
Lead developer: AliveGen
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

ALG-903 is an experimental therapeutic candidate currently in the discovery stage of development by AliveGen for the treatment of cancer. AliveGen is a biotechnology company focused on developing novel protein therapeutics that modulate the TGF-beta (Transforming Growth Factor-beta) superfamily signaling pathways. While specific details regarding the molecular target and mechanism of action for ALG-903 have not been publicly disclosed, the company's platform typically utilizes recombinant fusion proteins and ligand traps to address diseases involving muscle wasting, metabolic disorders, and oncology. The program represents AliveGen's expansion into the oncology space, leveraging its expertise in TGF-beta superfamily biology.

Beyond the preview

Go deeper on ALG-903.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALG-903.

Explore the full profile